Quest joins breast cancer gene-testing market

Share this article:

Quest's new BRCA test may loosen Myriad's hold on the genetic cancer testing market. The diagnostics firm is now selling tests for the two cancer genes that are linked to breast and ovarian cancer—BRCA1 and BRCA2—and for which Medicare pays around $3,400 when using Myriad's version. Bloomberg reports that Quest plans on charging $2,500.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.